Maraviroc

Major

Maraviroc Abametapir Increased exposure of CYP3A4 substrate Details Maraviroc Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Maraviroc Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Maraviroc Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Maraviroc Ketoconazole Topical Extina® Foam Increased maraviroc exposure and an increased maraviroc-related adverse reactions Details Maraviroc Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Maraviroc Lenacapavir Injection Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Maraviroc Lenacapavir Oral Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Maraviroc Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Maraviroc Adagrasib Krazati Increased exposure to CYP3A/P-gp substrates Details Maraviroc Apalutamide Erleada Reduced maraviroc exposure and reduced efficacy of maraviroc Details Maraviroc Atidarsagene Autotemcel Lenmeldy Interference with the manufacturing of atidarsagene autotemcel Details Maraviroc Avacopan Tavneos Increased CYP3A4 substrate exposure Details Maraviroc Berotralstat Orladeyo Increased P-gp substrate exposure Details Maraviroc Boceprevir Increased maraviroc exposure Details Maraviroc Carbamazepine Carbatrol Reduced maraviroc exposure Details Maraviroc Ceritinib Zykadia Increased maraviroc exposure Details Maraviroc Clarithromycin Biaxin Increased maraviroc exposure Details Maraviroc Cobicistat Tybost Increased maraviroc exposure Details Maraviroc Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Maraviroc Duvelisib Copiktra Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Maraviroc Enzalutamide Xtandi Reduced maraviroc exposure Details Maraviroc Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Maraviroc Etuvetidigene Autotemcel An increased risk of interference with the manufacturing of etuvetidigene autotemcel Details Maraviroc Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Maraviroc Fexinidazole An increased CYP3A4 substrate exposure Details Maraviroc Fluconazole Diflucan Increased sensitive CYP3A4 substrates exposure Details Maraviroc Fosnetupitant Increased exposure of CYP3A4 substrate Details Maraviroc Fosphenytoin Cerebyx Reduced maraviroc exposure Details Maraviroc Idelalisib Zydelig Increased maraviroc exposure Details Maraviroc Indinavir Increased maraviroc exposure Details Maraviroc Itraconazole Sporanox Increased maraviroc exposure Details Maraviroc Ivosidenib Tibsovo Reduced maraviroc exposure and risk of loss of efficacy Details Maraviroc Ketoconazole Extina Increased maraviroc exposure and an increased maraviroc-related adverse reactions Details Maraviroc Larotrectinib Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Maraviroc Lenacapavir Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Maraviroc Letermovir Prevymis Increased CYP3A substrate exposure Details Maraviroc Lonafarnib Zokinvy Increased maraviroc exposure Details Maraviroc Lumacaftor Reduced maraviroc exposure Details Maraviroc Mifepristone Korlym Increased maraviroc exposure Details